Japan IP Court upholds revocation of Boehringer's diabetes drug-dosage patent
Japan’s Intellectual Property High Court upheld the invalidation of Boehringer Ingelheim’s patent for its diabetes drug, finding that the claimed regimen was a routine refinement within known ranges rather than a...To view the full article, register now.
Already a subscriber? Click here to view full article